bicaluplex 150mg potahovaná tableta
teva pharmaceuticals cr, s.r.o., praha array - 13723 bikalutamid - potahovaná tableta - 150mg - bikalutamid
bicaluplex 50mg potahovaná tableta
teva pharmaceuticals cr, s.r.o., praha array - 13723 bikalutamid - potahovaná tableta - 50mg - bikalutamid
bicalutanorm 150mg potahovaná tableta
+pharma arzneimittel gmbh, graz array - 13723 bikalutamid - potahovaná tableta - 150mg - bikalutamid
bikalard 150mg potahovaná tableta
ardez pharma, spol. s r.o., kosoř array - 13723 bikalutamid - potahovaná tableta - 150mg - bikalutamid
lanbica 150mg potahovaná tableta
sandoz s.r.o., praha array - 13723 bikalutamid - potahovaná tableta - 150mg - bikalutamid
lanbica 50mg potahovaná tableta
sandoz s.r.o., praha array - 13723 bikalutamid - potahovaná tableta - 50mg - bikalutamid
binabic 150mg potahovaná tableta
vipharm s.a., ożarów mazowiecki array - 13723 bikalutamid - potahovaná tableta - 150mg - bikalutamid
binabic 50mg potahovaná tableta
vipharm s.a., ożarów mazowiecki array - 13723 bikalutamid - potahovaná tableta - 50mg - bikalutamid
firmagon
ferring pharmaceuticals a/s - degarelix - prostatetické novotvary - endokrinní terapie - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
xtandi
astellas pharma europe b.v. - enzalutamid - prostatetické novotvary - endokrinní terapie - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.